 The purpose of this study is to assess the Aranesp dose administered intravenously IV once weekly to maintain hemoglobin Hgb levels in hemodialysis subjects who are either recombinant human erythropoietin rHuEPO naïve or subjects converted from rHuEPO therapy administered IV thrice weekly TIW. 